IL36B and Guillain-Barre syndrome: Meanwhile, serum IL-36β levels in the acute phase of GBS patients were slightly higher than those in HCs, while there was no significant difference between serum IL-36β levels of patients with GBS in the recovery phase and these in the acute phase or in HCs (P = .019, P = .297, and P = .091, respectively, Fig. 1b).